Research

Antisense oligonucleotide (AON) therapy for Stargardt disease type 1 (STGD1) provides a proof of concept with effective restoration of correct ABCA4 transcript splicing. 

Researchers at ProQR Therapeutics, an RNA company based in Leiden, the Netherlands, and with researchers at Radboud University Medical Center in Nijmegen, have reported results… Read More »Antisense oligonucleotide (AON) therapy for Stargardt disease type 1 (STGD1) provides a proof of concept with effective restoration of correct ABCA4 transcript splicing. 

AI (artificial intelligence) study on multimodal images of RP patients shows significant impacts from both structural and functional evaluations. 

Researchers at the Shiley Eye Institute, University of California, San Diego, has reported results of AI (artificial intelligence) methods providing significantly accurate outcomes over manual… Read More »AI (artificial intelligence) study on multimodal images of RP patients shows significant impacts from both structural and functional evaluations. 

A systematic literature review on the epidemiology of RPE65 mutations report significant variations in the literature within countries as well as regions.

A systematic review on the epidemiology of RPE65 mutations reported in the literature showed that there were significant variations of RPE65 proportions within countries as… Read More »A systematic literature review on the epidemiology of RPE65 mutations report significant variations in the literature within countries as well as regions.

Five-year real-world results on intravitreal fluocinolone treatment of chronic diabetic macular oedema (DMO) has shown improved or stabilised VA

Researchers at the Birmingham and Midland Eye Centre, UK, has reported five-years’ of real-world results from the application of the fluocinolone acetonide implant (ILUVIEN), for… Read More »Five-year real-world results on intravitreal fluocinolone treatment of chronic diabetic macular oedema (DMO) has shown improved or stabilised VA